Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease.

Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease.

At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.

Lyterian Therapeutics

Ingrid Wertz

Veronica Kuiper

Julie Kim

Jonathan Baell

Tracy Yuen

The Research and Development team at Lyterian Therapeutics focuses on innovating and advancing therapies that leverage physiological protein mechanisms to address disease. By conducting rigorous cell assays, validating genetic targets, and translating scientific discoveries into therapeutic solutions, the team works collaboratively to create effective medicines that promote healing and restore health in patients.

Research and Development

About

Team members

Other teams at Lyterian Therapeutics

Leadership Team